cabazitaxel, docetaxel, mitoxantrone, satraplatin-Shanghai Jiao Tong University School of Medicine-prostate cancer

This entry refers to a Phase II-III randomized clinical trial (NCT03258320) sponsored by the Shanghai Jiao Tong University School of Medicine. The study evaluates the efficacy of four distinct chemotherapy agents—cabazitaxel, docetaxel, mitoxantrone, and satraplatin—administered as neoadjuvant single-agent therapies in patients with high-risk localized prostate cancer prior to radical prostatectomy. The trial investigates whether preoperative chemotherapy can better control tumor progression before the disease converts to a castration-resistant prostate cancer (CRPC) state. The agents involved represent different pharmacological classes: cabazitaxel and docetaxel are taxane-based microtubule stabilizers; mitoxantrone is an anthracenedione that intercalates DNA and inhibits topoisomerase II; and satraplatin is an oral platinum-based compound that induces DNA damage through cross-linking.

Other names

Neoadjuvant CDMS